Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team
Press release

Redeye: Cellavision Q2 - Mostly in line with some minor issues

CellaVision

Redeye’s view on the Q2 report. The organic growth was decent, while the gross margin development comprised most of the deviation compared to the results. We have decreased our sales estimates slightly due to uncertainty in the Americas and decreased our gross margin assumptions for the rest of 2024 and for the following years. With these changes and balance sheet adjustments, we have slightly increased our Base case to SEK 250 (245) and fair value range of SEK 165 – 388 per share

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments


Cellavision Q2 - Mostly in line with some minor issues

Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.